Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, Phase 2, open label, parallel trial to evaluate an effect
of pemetrexed alone on nonsquamous non-small cell lung cancer (NSCLC) in a second-line
setting (such as progression-free survival [PFS], disease control rate, best response rate,
time to treatment failure [TTTF], overall survival [OS] and 1-year survival rates) compared
to pemetrexed plus erlotinib combination.